Articles tagged with Vaccine Development
The European Vaccines Hub for Pandemic Readiness (EVH) is a pan-European center that integrates excellence in vaccine research, human monoclonal antibody development, clinical trials, and scalable manufacturing. EVH aims to drive innovation and ensure strategic autonomy in vaccine R&D and manufacturing.
A study found that adults hospitalized for RSV had significantly higher odds of cardiac events compared to those with COVID-19 or influenza. The findings suggest that preexisting cardiovascular risk patients should consider vaccination against respiratory viral infections.
Researchers from the University of Cincinnati have engineered bacteria to deliver antiviral therapies and vaccines orally, bypassing traditional methods. The engineered bacteria use outer-membrane vesicles as self-propelled delivery vehicles, targeting mucosal surfaces to provide mucosal immunity.
Researchers from Amsterdam UMC have made a breakthrough in developing an HIV vaccine with a germline-targeting strategy, inducing immune responses in participants. The phase one trial showed promising results, suggesting the potential for this approach to be further developed into a vaccine.
Researchers from Japan evaluate the LC16m8 vaccine, an attenuated vaccinia virus strain, for its efficacy and safety against mpox. The study confirms the vaccine's ability to induce strong immune responses and protect against mpox in mice, monkeys, and humans.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
A novel vaccine platform uses genetically fused antigen to albumin, which is actively transported across the mucosal barrier by FcRn receptor. This results in protective systemic and mucosal antibody responses against SARS-CoV-2 and influenza A.
The review highlights the limitations of existing dengue vaccines, such as CYD-TDV and TAK-003, and the urgent need for more effective vaccines to protect millions of people. The Butantan-DV vaccine has shown promise with its single-dose regimen, but its efficacy against DENV-3 and DENV-4 is still unclear.
The BNT162b2 vaccine not only targets the COVID-19 virus but also helps reduce and control innate inflammation to other bacterial and fungal pathogens. By reprogramming innate immune cells, the vaccine reduces pro-inflammatory mediators, providing potential benefits beyond its primary target.
A mathematical modeling study suggests that sustained HIV remission or eradication could consistently reduce new HIV infections among men who have sex with men (MSM) in the Netherlands. However, transient remission with a risk of rebound may increase new infections if not closely monitored.
A new vaccine platform developed at the University at Buffalo has demonstrated complete protection in mice against a deadly variant of bird flu. The vaccine, which combines key proteins hemagglutinin and neuraminidase, shows promise as a versatile and easy-to-produce vaccine that could be effective against evolving bird flu strains.
Researchers from the International Institute of Molecular and Cell Biology in Warsaw discovered a crucial role of enzyme TENT5A in extending poly(A) tails of therapeutic mRNA molecules, making them more stable and effective. Macrophages play a key role in vaccine effectiveness, capturing and neutralizing 'intruders' after administration.
Cervical cancer cases worldwide reached 622,301 in 2022, with significant variations in age-standardized incidence rates across regions. Targeted prevention programs, especially HPV vaccination in low-income countries, are essential to reduce the global health burden.
The University of Virginia has appointed Dr. Mark T. Esser as the inaugural head of its Manning Institute, a $350 million facility aimed at transforming healthcare and accelerating new treatments. Esser brings decades of experience in developing new medical breakthroughs and will foster an ecosystem of innovation to attract biotechnolo...
A new study reveals that the US national vaccine strategy saved more money than it spent on testing, buying and delivering COVID-19 vaccines after just one year. The analysis found that the vaccines reduced serious illness and deaths, resulting in significant cost savings.
Researchers at HKU and CVVT create a nasal spray vaccine offering single-dose protection against H5N1 infection, inducing comprehensive immunity in the upper respiratory tract. The vaccine's high safety profile and ability to curb viral transmission make it a critical reserve for future outbreaks.
Researchers at the University of Maryland discovered a way to predict treatment success for cutaneous leishmaniasis, a devastating skin infection. By analyzing a patient's immune system, they identified a distinctive pattern that distinguishes responders from non-responders, with 90% accuracy.
A promising new target for a Lyme disease vaccine has emerged: the Lyme bacterial protein CspZ. Genetic engineering revealed hidden regions that trigger a strong immune response. The modified protein promotes continuous production of protective antibodies, reducing the need for booster shots.
The Vaccine Innovation Center at Korea University's College of Medicine successfully held the 2025 Vaccine Expert Training Program, attended by over 380 experts and researchers from various fields. The program aims to foster domestic vaccine R&D experts and promote the development of commercially available vaccines.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
The MOPEVACLAS vaccine candidate is being tested in a Phase I clinical trial for its safety and immune response in humans. The vaccine targets Lassa fever, a hemorrhagic disease responsible for thousands of deaths worldwide each year.
The University of Texas at Arlington expert discusses the state's largest outbreak in 30 years, with fewer people getting vaccinated contributing to its spread. The MMR vaccine is 97% effective against measles and has been proven safe despite misconceptions about its safety.
Many teenagers enter adulthood with significant risk factors for cardiovascular disease, and emerging adulthood is a key time to address these risks. Interventions such as health practices, lifestyle changes, and improved access to healthcare can help reduce the risk of developing future cardiovascular disease.
A new reverse genetics system for African swine fever virus (ASFV) has been developed, enabling rapid vaccine development and research into the virus's biology. This technology can be adapted for other viruses, including lumpy skin disease, Zika, chikungunya, and Ebola viruses.
Researchers from La Jolla Institute for Immunology and UC San Diego discover Zika virus blocks dendritic cells' ability to alert T cells, while dengue virus stimulates pro-inflammatory cytokines, leading to a stronger but uncontrolled immune response. Understanding these differences is key to developing life-saving vaccines.
Researchers developed a universal vaccine that removes sugar molecules from coronavirus spike proteins, creating effective antibodies. The vaccine showed improved protection against various variants and potential applications for cancer treatment.
A growing body of evidence suggests a significant link between human papillomavirus (HPV) and heart disease. Researchers pooled data from nearly 250,000 patients in seven studies, finding HPV-positive individuals had a 40% higher likelihood of developing cardiovascular disease.
Researchers have made progress in understanding how Streptococcus pneumoniae constructs its capsule, a critical target for vaccine development. The study identified three categories of transporters that facilitate sugar building block transport, with relaxed specificity transporters posing potential risks to bacterial growth.
A TB vaccination has been shown to boost the immune system of bladder cancer patients, reducing cancer recurrence rates by up to 75% in a small pilot study. The vaccine was well-tolerated with no side effects and showed promising results in improving patient outcomes.
A study published in The Lancet Infectious Diseases found that a single dose of the Imvanex vaccine provides 84% protection against Mpox for HIV-negative individuals, but offers limited protection for those living with HIV. The study recommends that all at-risk groups, particularly those with HIV, receive two doses of the vaccine to ac...
A Phase 1 clinical trial is enrolling up to 55 healthy adults to test the safety and immunogenicity of a candidate Lassa vaccine. The trial aims to prevent Lassa fever, a viral hemorrhagic disease that can cause permanent hearing loss.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
A study has established the importance of immunoglobulin A in generating a response to pneumonia vaccines. The research found that poor regulation of gut microbiota can lead to an inadequate immune response, leaving individuals vulnerable to respiratory infections.
A major clinical trial has identified ensitrelvir as an effective medication to prevent symptomatic COVID-19 in people exposed within households. The trial showed a 67% reduction in risk of illness among participants taking the antiviral compared to those given a placebo.
A recent study by Oregon Health & Science University and Weill Cornell Medicine has found that CMV lacking a certain viral protein complex can still be transmitted and cause significant harm to the developing fetus. The research suggests that additional vaccine targets need to be identified and explored to provide superior protection.
Researchers at the University of Leeds have developed a more affordable and lower-risk polio vaccine using virus-like particles (VLPs). VLPs mimic the outer protein shell of poliovirus but are empty inside, making them non-infectious yet capable of triggering an immune response.
The U.S. research ecosystem, fueled by high-performance computing, is facing a critical moment due to slow infrastructure growth and funding cuts. The National Science Foundation's staffing cuts will slow down the process of innovation, potentially harming the country's competitive edge in research.
A new study has discovered how antibodies help protect against Strep A infections and is contributing to the development of a Strep A vaccine. The research used the world's only human challenge model for Strep A, which uncovered the power and potential for this model to accelerate vaccine development.
A new TB vaccine candidate has shown complete protection and a superior immune response in nonhuman primates compared to the existing BCG vaccine. The delta sigH vaccine resulted in a more balanced and effective elimination of the bacteria, with lower levels of inflammation and a different type of interferon triggered.
Researchers have identified powerful antibodies capable of neutralizing a wide range of norovirus strains, paving the way for designing a broadly effective norovirus vaccine. The discovery brings us closer to a vaccine that could provide lasting protection and prevent devastating effects of norovirus outbreaks.
A risk prediction model was developed to identify patients unlikely to complete HPV vaccination. The model uses patient demographics and clinical characteristics to guide targeted interventions, increasing vaccination rates among high-risk groups.
Richard Willson, a University of Houston professor, has been elected Fellow of the Royal Society of Chemistry for his contributions to the chemical sciences. He has developed innovative methods to detect viruses and other biological threats using glow-in-the-dark nanoparticles.
Researchers developed a new vaccine platform that provides robust, long-lasting protection against multiple flu strains and COVID-19. The vaccine boasts 100% survival rates in vaccinated mice following challenge with either virus.
Lyme disease is a bacterial infection transmitted by ticks, posing an increasing threat in the U.S. Montana State University's Patrick Secor will study adaptations in Borrelia burgdorferi to illuminate how it circumvents its host's immune system. The goal is to discover new vaccine antigens and develop more effective treatments.
Researchers analyzed protein-coding RNA transcripts from single cells and lung fluid of infected pigs, monitoring immune cell alterations triggered by PRRSV strains of varying virulence. They found that high-virulence PRRSV caused severe lung damage and immune imbalance, while less virulent strains led to delayed lung damage with fewer...
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
A US clinical trial will assess the safety and efficacy of a nasal COVID-19 vaccine developed using technology from Washington University in St. Louis. The trial, sponsored by the National Institute of Allergy and Infectious Diseases, aims to evaluate the vaccine's ability to induce strong immunity in the nose and upper respiratory tract.
A new biodegradable polymer-based delivery system efficiently transports mRNA, outperforming existing lipid nanoparticles in delivery efficiency and expression duration. The study also shows improved immune response results without liver accumulation or toxicity.
A broadly neutralizing antibody has been shown to protect monkeys against severe H5N1 avian flu disease. The antibody's stable structure ensures it can withstand virus variants, providing universal protection against a globally spreading airborne infection. Serum levels of the antibody remained stable for up to 12 weeks.
Researchers developed a new approach to quickly identify mutations that enable viral immune escape. By analyzing the effects of individual mutations in reverse, they found three key mutations in the spike protein responsible for immune evasion.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Researchers at the University of Queensland have identified a new henipavirus, Camp Hill virus, in shrews in Alabama, USA. The discovery suggests these viruses may be more globally distributed than previously thought, with implications for human health and vaccine development.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
Researchers developed MUNIS, a deep learning tool that predicts CD8+ T cell epitopes with high accuracy, potentially accelerating vaccine development. The tool was validated using experimental data from influenza, HIV, and EBV, demonstrating its potential to streamline vaccine design.
Southwest Research Institute's Risk Evaluation & Medical Decision Efficacy (REMEDY) tool supports agile medical decisions on countermeasures for chemical and biological threats. The REMEDY mission risk evaluations quantify risks and benefits of medical countermeasures, enabling operational planners to make informed decisions.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
Researchers develop BEND lipids to improve LNP mRNA delivery and gene editing by breaking through the endosomal membrane. The new lipids outperform existing LNPs used in COVID-19 vaccines, with improved efficacy rates up to tenfold.
A West Virginia University legal scholar argues that current laws favor biologic drugs with longer exclusivity periods, affecting their pricing. The scholar suggests reducing exclusivity for biologics to bring them in line with small-molecule drugs, which could lower drug costs.
Cancer vaccines hold transformative potential, leveraging neoantigens to activate the immune system against tumors. UK researchers are positioning themselves for a strategic shift in cancer vaccine trials, recognizing opportunities for improvement.
A novel diagnostic system called TwinDemic Detection offers simultaneous and rapid detection of SARS-CoV-2 and influenza A virus. The system has a detection limit of 0.46 picomolar for CoV and 0.39 pM for IAV, correctly predicting positive and negative samples in high percentages.